Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
US generic drugmaker Impax Laboratories today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration containing a paragraph IV certification for a generic version of Aubagio. 6 January 2017
David-Alexandre “DA” Gros has joined Neurocrine Biosciences as president and chief operating officer, the American biotech group announced today. 6 January 2017
In a Securities and Exchange Commission (SEC) filing on Tuesday, US firm PixarBio announced that it has issued a press release, dated January 3, 2017, in which the company announced its intention to acquire InVivo Therapeutics. 4 January 2017
USA-based privately-held drug developer Sharp Edge Labs has entered into a drug discovery collaboration agreement with Japan’s Sumitomo Dainippon Pharma. 4 January 2017
The Russian General Prosecutor's Office will check information about the bribes that were allegedly paid by Teva Russia to a certain Russian top official for the assistance in the promotion its products during state tenders for public procurement of drugs in Russia. 27 December 2016
Positive Phase III results of Swiss pharma giant Roche’s Ocrevus (ocrelizumab) have been published in the New England Journal of Medicine. 22 December 2016
US biotech major Biogen has now selected a new chief executive to replace outgoing incumbent George Scangos, who has led the company since 2010 but announced his intention to leave last year, from its own ranks. 20 December 2016
Based on a US Food and Drug Administration review of a large clinical trial that FDA required the drug companies to conduct, the agency has determined the risk of serious side effects on mood, behavior, or thinking with the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) is lower than previously suspected. 19 December 2016
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended seven new medicines for marketing authorization at its December 2016 meeting. 17 December 2016
USA-based Baxter International has announced the acquisition of an India-based business to accelerate its strategy to become a global leader in the injectables pharmaceutical space. 16 December 2016
Evotec has entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. 16 December 2016
The USA's Castle Creek Pharmaceuticals has acquired the US rights to the vertigo drug Arlevert (cinnarizine, dimenhydrinate) from family-run German company Hennig Arzneimittel. 15 December 2016
The Canadian government has announced new legislation aimed at tackling the growing problem of
opioid drug abuse, citing statistics that record numbers of Canadians have died from drug overdoses this year. 13 December 2016
Eisai has presented promising new data on its beta amyloid cleaving enzyme inhibitor elenbecestat at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego, California. 13 December 2016
Family-owned German drugmaker Grünenthal has negotiated a deal to acquire rights to market a dermal patch for the treatment of peripheral neuropathic pain (PNP) in the EMEA region. 12 December 2016
Rather like Kite’s registrational Zuma-1 trial of KTE-C19 in lymphoma, Novartis’ Eliana study has generated a fileable response rate. In the case of the Swiss firm’s rival CAR-T therapy, CTL019, this is in childhood leukemia patients, says EP Vantage, the editorial arm of the Evaluate group. 10 December 2016
As Eli Lilly’s Phase III Alzheimer’s disease drug candidate solanezumab was dropped due to disappointing results, the chief focus at the current AD conference turned to an early-stage candidate form biotech firm Biogen. 10 December 2016
Not burnt by its disappointment with Alzheimer’s candidate solanezumab, US pharma major Eli Lilly has announced a worldwide agreement with Anglo-Swedish company AstraZeneca on another drug focused on the amyloid beta pathway. 9 December 2016